Juen Kim, MD
Allergy & Immunology · Philadelphia, PANPI 1578862413
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,967 of the $7,542 with a category attached, or 79.1%. 22 manufacturers reported payments, led by Sanofi at 33.1% of the total. 2025 is the largest year on record at $2,994, 6.8 times the $441 reported in 2021.
Across 193 payments — averaging $39.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$1K
- Optinose US, Inc.$571
- GSK$540
- Alk-abello, Inc$312
- plus $1K from 16 others
What the payments were for
- Consulting fees$1,44619%
- Food & beverage$5,96779%
- Education$1302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 26 | $2,494 |
| Regeneron Healthcare Solutions, Inc. | 45 | $1,190 |
| AstraZeneca | 35 | $1,045 |
| Optinose US, Inc. | 22 | $571 |
| GSK | 20 | $540 |
| Alk-abello, Inc | 6 | $312 |
| CSL Behring | 12 | $265 |
| AbbVie | 3 | $260 |
| Novartis | 7 | $167 |
| Dermavant Sciences, Inc. | 2 | $149 |
| Blueprint Medicines Corporation | 2 | $148 |
| Regeneron | 1 | $110 |
| Biocryst US Sales Co., LLC | 1 | $65 |
| Genentech USA, Inc. | 2 | $43 |
| Electromed, Inc. | 1 | $40 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $39 |
| Kaleo, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Organon | 1 | $15 |
| Bio Products Laboratory USA, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,542 in reported general payments places this provider in the 65th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 17 | $114,753 |
| Dupixent PenDupilumab | 12 | $46,786 |
| Fluticasone Propionate | 46 | $809 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $790 |
| Famotidine | 14 | $526 |
| Montelukast Sodium | 24 | $387 |
| Azelastine Hcl | 13 | $299 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Philadelphia
- Drew WeissmanPhiladelphia$12.8M
- Arnold LevinsonPhiladelphia$95K
- Elias AklPhiladelphia$80K
- Neha SirohiPhiladelphia$62K
- John BossoPhiladelphia$42K
- Marc GoldsteinPhiladelphia$22K
- Raquel EmpedradPhiladelphia$21K
- Karin Flynn-RoddenPhiladelphia$15K
- Donald DvorinPhiladelphia$10K
- Irene HaralabatosPhiladelphia$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.